Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox

Toro, Jorge R.; Sánchez, S. González; Turiansky, George W.; Blauvelt, Andrew

doi:10.1016/s0733-8635(02)00116-x

Cited by 29 publications

(20 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cidofovir has been shown to reduce E6 and E7 expression and to reduce the metastatic properties of HPV-positive tumor cells [58]. Cidofovir was first shown to have an effect in anogenital condyloma [59]. A study in CIN3 showed complete regression in seven out of 15 women (47%), after three treatments on alternate days with topical cidofovir, and a partial response was seen in five patients (33%) [60].…”

Section: Development Of Novel Treatmentsmentioning

confidence: 99%

Therapy of Human Papillomavirus-Related Disease

Stern

Burg

Hampson

et al. 2012

Vaccine

155

124

View full text Add to dashboard Cite

This chapter reviews the current treatment of chronic and neoplastic HPV-associated conditions and the development of novel therapeutic approaches. Surgical excision of HPV-associated lower genital tract neoplasia is very successful but largely depends on secondary prevention programmes for identification of disease. Only high-risk HPV-driven chronic, preneoplastic lesions and some very early cancers cannot be successfully treated by surgical procedures alone. Chemoradiation therapy of cervical cancer contributes to the 66–79% cervical cancer survival at 5 years. Outlook for those patients with persistent or recurrent cervical cancer following treatment is very poor. Topical agents such as imiquimod (immune response modifier), cidofovir (inhibition of viral replication; induction apoptosis) or photodynamic therapy (direct damage of tumour and augmentation of anti-tumour immunity) have all shown some useful efficacy (~50–60%) in treatment of high grade vulvar intraepithelial neoplasia. Provider administered treatments of genital warts include cryotherapy, trichloracetic acid, or surgical removal which has the highest primary clearance rate. Patient applied therapies include podophyllotoxin and imiquimod. Recurrence after “successful” treatment is 30–40%. Further improvements could derive from a rational combination of current therapy with new drugs targeting molecular pathways mediated by HPV in cancer. Small molecule inhibitors targeting the DNA binding activities of HPV E1/E2 or the anti-apoptotic consequences of E6/E7 oncogenes are in preclinical development. Proteasome and histone deacetylase inhibitors, which can enhance apoptosis in HPV positive tumour cells, are being tested in early clinical trials. Chronic high-risk HPV infection/neoplasia is characterised by systemic and/or local immune suppressive regulatory or escape factors. Recently two E6/E7 vaccines have shown some clinical efficacy in high grade VIN patients and this correlated with strong and broad systemic HPV-specific T cell response and modulation of key local immune factors. Treatments that can shift the balance of immune effectors locally in combination with vaccination are now being tested. This article forms part of a special supplement entitled “Opportunities for comprehensive control of HPV infections and related diseases” Vaccine Volume 30, Supplement X, 2012.

show abstract

Section: Development Of Novel Treatmentsmentioning

confidence: 99%

Therapy of Human Papillomavirus-Related Disease

Stern

Burg

Hampson

et al. 2012

Vaccine

155

124

View full text Add to dashboard Cite

show abstract

“…[78][79][80] Many case reports have also suggested topical cidofovir as a promising, efficacious treatment for various dermatologic conditions, including anogenital squamous cell carcinoma in situ, vulvar intraepithelial neoplasia, Bowenoid papulosis, and molluscum contagiosum. 77 Although dose-related mild to moderate application site reactions, including inflammation, erosion, and burning sensations, were seen in 20% to 39% of patients, no systemic toxicities were observed. 76,77,81 Topical cycloserine for hyperpigmentation in pityriasis versicolor…”

Section: Chemotherapy Of Microbial Diseases Topical Cidofovir For Thementioning

confidence: 91%

“…77 Although dose-related mild to moderate application site reactions, including inflammation, erosion, and burning sensations, were seen in 20% to 39% of patients, no systemic toxicities were observed. 76,77,81 Topical cycloserine for hyperpigmentation in pityriasis versicolor…”

Section: Chemotherapy Of Microbial Diseases Topical Cidofovir For Thementioning

confidence: 91%

“…In subsequent case reports, the effectiveness of topical cidofovir for verruca, either in immunocompetent or immunocompromised patients, has been reported. 76,77 Similarly, 3 RDBPCTs demonstrated its efficacy for the treatment of mucocutaneous herpes simplex infection, cervical intraepithelial neoplasia, and anogenital warts. [78][79][80] Many case reports have also suggested topical cidofovir as a promising, efficacious treatment for various dermatologic conditions, including anogenital squamous cell carcinoma in situ, vulvar intraepithelial neoplasia, Bowenoid papulosis, and molluscum contagiosum.…”

Section: Chemotherapy Of Microbial Diseases Topical Cidofovir For Thementioning

confidence: 99%

See 1 more Smart Citation

Topical use of systemic drugs in dermatology: A comprehensive review

Chiu¹,

Tsai²

2011

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…There is a precedent for using topical cidofovir, 1% and 3%, in dermatology for cutaneous HSV,5 human papillomavirus,6 and molluscum contagiosum 7. Intravenous cidofovir is also used in patients with acyclovir-resistant HSV skin disease 8,9.…”

Section: Commentmentioning

confidence: 99%

Successful Treatment of Acyclovir-Resistant Herpes Simplex Virus With Intralesional Cidofovir

Castelo‐Soccio¹

2010

Arch Dermatol

View full text Add to dashboard Cite

Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox

Cited by 29 publications

References 49 publications

Therapy of Human Papillomavirus-Related Disease

Therapy of Human Papillomavirus-Related Disease

Topical use of systemic drugs in dermatology: A comprehensive review

Successful Treatment of Acyclovir-Resistant Herpes Simplex Virus With Intralesional Cidofovir

Contact Info

Product

Resources

About